Abstract: Embodiments of the invention relate to methods for the manufacture of a protein-bound cannabinoid, comprising: obtaining a cannabinoid or cannabis in a form selected from the group consisting of cannabis smoke, cannabis vapor, cannabinoid solution and cannabis extract, and combining the cannabis smoke, vapor, cannabinoid solution or cannabis extract with an aqueous solution or suspension comprising a plasma protein to form a protein-bound cannabinoid. Further embodiments relate to aqueous solutions comprising a plasma protein-bound cannabinoid and pharmaceutical compositions comprising cannabinoids bound to plasma protein.

Abstract: A method of producing pure cannabidiol (CBD) isolate crystals including the steps of extracting the CBD compound from a cannabis plant; winterizing to remove fats, waxes and chlorophyll from the CBD extract; filtering the CBD extract through a series of filter plates; removing carboxylic acid and CO2 from the CBD extract; removing impurities from the CBD extract by distillation; and crystallizing the purified CBD extract to produce pure CBD isolate crystals and chopping the pure CBD isolate crystals to produce crystals of between 200 and 600 microns in size. A further embodiment includes the steps of grinding the crystals to produce micro-particles of between 1 and 5 microns and releasing the micro-particles into an air environment.

Abstract: Compositions and methods of manufacturing mineral pitch resin compositions comprising at least one of a cannabinoid, a terpene, a terpenoid, an essential oil and a fatty acid are provided. Such mineral pitch resin compositions may be safely consumed orally, topically or otherwise, and have numerous health benefits.

Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.

Abstract: The present invention relates to an edible composition comprising plant sterol ester and/or plant stanol ester and triglyceride fat usable for lowering serum LDL cholesterol. The composition further comprises oligosaccharides and sugars. The composition can preferably be used in dietary supplements, fillings and toppings.

Abstract: Disclosed is a method of cleansing facial skin. The method can include obtaining an apparatus that includes: (a) a water-permeable absorbent material, wherein the water-permeable absorbent material is a sponge, cloth, or mesh which has a first outer surface and a second outer surface; and (b) a composition comprising a plant material, a plant extract, or a combination thereof, wherein the plant material, the plant extract, or the combination thereof comprises Aloe vera extract and a Matricaria recutita (chamomile) extract. The method can also include contacting the apparatus with water heated to 30° C. to 100° C. for a sufficient period of time so as to release, solubilize, or release and solubilize the plant material, the plant extract, or the combination thereof to yield a treated apparatus and contacting and cleansing the facial skin with the treated apparatus.

Abstract: An improved method for making cannabinoids from plant material utilizes the following steps. Plant material is contacted with an aqueous alkaline solution containing a hydroxide base and essentially no organic solvents, thereby extracting cannabinoids including carboxylic acids and salts and producing an alkaline extract. Non-soluble plant material is removed from the alkaline extract to produce a clarified alkaline extract. The extracted cannabinoids are decarboxylated and the decarboxylated cannabinoids are crystallized/precipitated from the clarified alkaline extract at a pH greater than 7.

Abstract: The invention relates to a novel extract from the resin of a plant of the genus Boswellia (Burseraceae). The invention further relates to a composition comprising the novel extract, in particular a pharmaceutical composition or a cosmetic composition, or a food supplement, a food or a beverage comprising the extract. Further, the invention concerns the use of the extract and the respective compositions, in particular the use of the extract or a composition comprising the extract in the cosmetic or therapeutic field as well as in food supplements. The invention also relates to the novel extract and the respective compositions for use in the treatment and/or prevention of a disease. A method of treatment and/or prevention of a neurodegenerative disease is further provided. A process is also provided, by which the novel extract is obtained.

Abstract: Proposed is a Geumhwagyu extract as an active ingredient. The Geumhwagyu extract of the present disclosure inhibits the differentiation of pre-adipocytes by inducing the degradation of CEBP-? and inhibits the expression of CEBP-?, PPAR?, Perilipin-1, Adiponectin, FABP4, etc., to suppress the accumulation of lipids in adipocytes. It can be easily used as a composition for preventing or managing obesity by inhibiting it and lowering the content of TG (Triacylglycerol) to show anti-obesity activity.

Abstract: The present invention relates to concentrates obtained from extraction from Cannabis, preferably cannabinoid and/or terpene concentrates, and formulation of the concentrates, particularly for use for direct vaporization, infusion into edible matrices, in electronic inhalation devices, and as nutraceuticals.

Abstract: Provided is a plant extract-containing composition for reducing skin damage caused by ultraviolet radiation. The composition includes a combination of extracts of spinach, black tea, green tea, Pu-erh tea, Four Seasons Spring tea, red wine, blueberry, grape seeds, citrus, or green coffee beans.

Abstract: The present invention relates to a pharmaceutical composition and health functional food for preventing or treating neurodegenerative diseases which include a flower extract of Daphne genkwa or fractions thereof as an active ingredient. The pharmaceutical composition and health functional food for preventing or treating neurodegenerative diseases are, not like extracts from stems and/or roots of Daphne genkwa, free from genotoxicity and have superior prophylactic or treatment effects against neurodegenerative diseases.

Abstract: A process for controlling a decarboxylation of acidic cannabinoids for an infused soluble fat product, such as a butter product, is disclosed. In one embodiment for producing a butter product, raw cannabis base material is dried, pulverized, heated, and cooled to produce a decarbed cannabis material. The decarbed cannabis material is mixed with unsalted butter in an about 22:1 to and about 26:1 ratio, by weight, at ambient temperature and pressure, to produce a heterogenous butter material. The heterogenous butter material is canned and subjected to in-container thermal processing, including agitation during the thermal processing. The resulting heterogenous butter material is separated before cooling produces the butter product.

Abstract: A process of converting cannabidiol (CBD) to ?8-tetrahydrocannabinol (?8-THC) or ?9-tetrahydrocannabinol (?9-THC) can enable mass production of ?8-THC and/or ?9-THC, achieve greater yields and higher purity in comparison to previously reported processes while eliminating the use of organic solvent. The resultant hemp-derived ?8-THC can be mixed with and absorbed by natural extracts, including tea extract, starch, sugar, lecithin, and other emulsifiers. ?8-THC used in edible, topical and vaping products such as powdered ?8-THC food ingredients, tablets or pills, suppositories, and vape formulations are disclosed. Further described are beverages and baked goods utilizing or incorporating the tablets or powdered ?8-THC to create edible products containing an emulsified, tasteless, and odorless dose of ?8-THC. The disclosure also describes a rectal suppository designed to provide improved comfort of use.

Abstract: A liquid capsule of cannabis, ginseng, and turmeric rhizome oil blend consisting essentially of an oil blend of cannabis oil, turmeric rhizome oil, and ginseng oil in a liquid capsule. There is less than 4 ppm of tetrahydrocannabinol (THC) in the oil blend.

Abstract: In alternative embodiments, provided are industrial processes and methods for extracting or removing cannabinoids, flavonoids and terpenes from plant materials such as trichomes. In alternative embodiments, the cannabinoids, flavonoids and terpenes are extracted or removed from the plant materials using a non-polar, organic solvent, or a mixture of non-polar, organic solvent and polar, organic solvent.

Abstract: The invention relates to a topical formulation in order to deliver an effective amount of broad-spectrum cannabidiol ointment, in conjunction with active ingredients, menthol and camphor. This invention is for the treatment of symptoms and improvement of sensation associated with peripheral neuropathy, particularly of the feet and hands. The present invention also provides for various topical application formulations.

Abstract: Disclosed are compositions, devices, and methods to prevent and recover from detrimental effects of alcohol consumption, including significant undesirable symptoms of a hangover consciously felt by the alcohol consumer, as well as those that may not be consciously experienced. The present technology comprehensively targets multiple negative effects of hangovers. In one aspect, a composition includes dihydromyricetin (DHM); and N-acetyl cysteine (NAC). The composition may further include Prickly Pear Extract, Milk Thistle, Ginger Root, Vitamins B, C, and E, electrolytes, and/or sugars.

Abstract: Films (ODFs) that include botanical extract are provided, as well as methods of making and using the same.

Abstract: A valerian composition includes valerian and an acidifying agent blended together in a pharmaceutically acceptable hydrogel-forming polymer matrix. An expedited release portion of the dosage form includes 5% to 50% of the valerian and is effective to release the valerian therein within 2 hours from placement in a 0.1 N HCl solution. A sustained release portion of the dosage form includes the remainder of the valerian and is effective to release the valerian therein within 10 hours from placement in a phosphate buffer with a pH of 6.8.